Advancing laboratory diagnostics: Beckman Coulter’s strategic vision for EEMEA healthcare

In this exclusive interview, Middle East Health talks to Nurgl Vatasever, Eemea Vice President, Beckman Coulter, about the latest diagnostic innovations and strategic direction of the company. With the systems test in one million samples worldwide every hour, Beckman Coulter continues to advance in the Medino laboratory through high performance analyzers such as DXI 9000 and automation solutions. Vatasever discusses how these technologies address the critical challenges of medical care, from the limitations of the workforce to the growing demand for diagnosis, while sharing ideas about emerging biomarkers and the company’s collaborative approach, US regions.

Middle East Health: Beckman Court has a world -renowned legacy in the diagnostic industry. How would it characterize the current position of the company in the global diagnostic industry and how unique it contributes to health systems in the US regions?

Nurg Vatasever: Every hour in the world, more than one million samples are tested in the diagnostic systems of Beckman Coulter, which affected 1.2 billion patients and more than three million doctors each year. Through our innovative diagnostic solutions, we focus on ensuring that Eemea clinical laboratories provide accurate diagnostic information to doctors and patients that allow high quality care.

What separates us is how we help health systems to address real challenges such as limited resources, limitations of the workforce and a growing demand. Our scalable portfolio, in immunoassay, chemistry, hematology, microbiology and communication analysis, helps laboratories more with less.

By automating key laboratory processes, we reduce the manual workload and improve the results of analysis of rapid and reliable samples. That means that doctors get the answers they need faster, and patients can start treatment before. It is about enabling better results with greater efficiency.

MEH: The launch of the DXI9000 immunoassay analyzer repeats a significant advance in diagnostic technology. Could you explain your technical capabilities, particularly through the ability to put and reduced sample volume requirements, are transforming clinical laboratory workflows and patient care?

Nurg Vatasever: The launch of the Dxi 9000 Immunoassay analyzer really marks a new chapter in diagnostic innovation. Its high performance capacity and high sensitivity immunoassay testing capabilities for central laboratories are outstanding characteristics, which allows laboratories to process a significant volume of samples with speed and precision. The ability to rationalize workflows and reduce response times is a change of play for laboratories that manage high wind loads under resource restrictions.

Middle East Health: Health systems face a assembly pressure to offer more precise diagnoses with less resources. How does the DXC 500i clinical analyzer address these challenges and what improvements in clinical decision making have observed its implementation?

Nurg Vatasever: The DXC 500i clinical analyzer is designed to bring automation to low performance space, partly for integrated health networks with multiple smaller laboratories. The DXC 500i combines advanced technology with an intuitive user interface, ensuring that the laboratories of all sizes can meet the growing demands of modern medical care. With putut of up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour, this analyzer offers precise and reliable critical results for timely clinical decision making. It addresses the challenge of delivering precise diagnoses with less resources when rationalizing workflows and reducing the need for manual intervention. This guarantees more consistent and reliable results, ultimately, helping laboratories to operate more efficiently without committing diagnosis.

Middle East Health: What emerging biomarkers or diagnostic parameters are its R&D channel that explores that it could transform the detection of early diseases into the next 3-5 years?

Nurg Vatasever: We are very excited about our pipe or diagnostic tests to address a wide range of diseases. For example, the DXI 9000 analyzer has demonstrated the ability to develop increasingly sensitive and clinically relevant trials. Taking advantage of this capacity, we are developing a blood -based Alzheimer’s disease test. Recently, the United States Drug and Food Administration (FDA) has granted the designation of innovative devices to the P-Tau217/-amiloid 1-42 ratio of Beckman Court. This blood test is designed to help medical care suppliers identify patients with amyloid pathology associated with Alzheimer’s disease.

Middle East Health: What collaboration initiatives have Beckman Court developed with health professionals to strengthen the accuracy and scalability of the diagnosis?

Nurg Vatasever: In Beckman Coulter Diagnostics, we give a great value to associations with all levels of interested parties, including health professionals, channel partners and institutions. We collaborate closely with the thesis partners to identify unattered needs, create personalized solutions, participate through thought leadership programs and boost continuous innovation. This approach helps us anticipate the future of diagnosis, optimize professional education and integrate advanced technologies to improve patient care.

Middle East health: educational associations or accelerate the adoption of advanced diagnostic platforms. What specific educational projects have your team implemented to ensure that health professionals can maximize the clinical utility of their technologies?

Nurg Vatasever: Education is a cornerstone of our strategy to support the adoption of advanced diagnoses. One of our key initiatives is the Beckman Coulter Dubai Vision Center, a dedicated learning center that offers certified services and application training, custom customer programs and scientific conferences. We provide interactive tutorials, practical workshops and integral training materials, all customized to meet the specific needs of laboratories throughout the US region.

Through the thesis educational associations, we make sure that health professionals are fully equipped to maximize the clinical utility of our technologies.

Middle East Health: The trajectory of his career has led him to this fundamental leadership role. What training experiences shaped their understanding of the challenges of the diagnostic sector and how these ideas report their strategic direction for the Eemea region?

Nurg Vatasever: Starting my career as the first engineer at Hitachi Medical Systems in Turkiye, I have had the opportunity to work in several geographies, including Russia, Eastern Europe, the Middle East and Africa. These experiences have provided me with a broad perspective on the medical care sectors challenges and unique opportunities. They formed my understanding of critical problems such as unequal access to diagnoses, infrastructure and limitations of the workforce.

They also reinforced the importance of scalable and locally relevant solutions and the power of strong associations. In Beckman Coulter Diagnostics, these ideas guide my strategic direction for the US region that is associated with our customs to expand access to high quality diagnoses, invest in education and excellence in the service, and collaborate to Strakeholers Cotgett

Middle East Health: Can you tell us a little about your leadership style? What is your method to build a productive work culture and effective employee participation?

Nurg Vatasever: My leadership style focuses on collaboration, empowerment and data -based decisions, with a strong emphasis on compassionate leadership. My goal is to create an environment where team members feel valued, reliable and motivated to take possession of their work. Open communication, empathy and continuous improvement are key to fosted success together.

To build a culture of productive work and an effective participation of employees, I am concentrated in the responsibility, respect and celebration of individual and team achievements. Priorizo ​​stay committed to my team, ensuring that everyone feels supported and empowered to grow in their roles. By reservoiring the psychological and mint of an open mentality, I encourage team members to express ideas freely without fear of judgment. This, combined with clear expectations and continuous comments, builds a basis of trust that strengthens the team’s ability to innovate and perform at your best.

About Nurgül Vatasever
Nurgül Vatasever is the US Vice President in Beckman Coulter. In addition to promoting commercial priorities, it is dedicated to promoting a high performance culture by providing strategic leadership, coaching and talent development throughout the region.

With extensive experience in the health industry, Nurgül has administered several markets in the Middle East, Africa, Turkey, Russia, the CEI countries and central Eastern Europe. He has played leadership roles of greater responsibility in sales, services, marketing and general management in Medtronic, Johnson & Johnson, Ge Healthcare and Hitachi Medical Systems.

On his 25 -year career on medical devices and the health industry, he has been recognized for his commitment to ethical leadership, cultivating a winning culture and prioritizing talent by attracting, developing and retaining the high performance of several teams.